Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AzentaFRA:BA3 -0.70%78 Net Margin % is 1.52% as of Jun. 2026, which is 89% below its 10-year median of 14.28. GuruFocus rates FRA:BA3 with a GF Score™ of 78/100 and a GF Value™ of €45.02 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 815 Medical Devices & Instruments companies, Azenta ranks worse than 69.69% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Azenta's Net Income for the
three
months ended in Jun. 2026 was €2.1 Mil. Azenta's Revenue for the
three
months ended in Jun. 2026 was €139.9 Mil. Therefore, Azenta's net margin for the quarter that ended in Jun. 2026 was 1.52%.
The historical rank and industry rank for Azenta's Net Margin % or its related term are showing as below:
FRA:BA3'
s Net Margin % Range Over the Past 10 Years
Min: -28.76 Med: 14.28 Max: 383.95
Current: -20.02
FRA:BA3's Net Margin % is ranked worse than 69.69% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: 2.2
vs FRA:BA3: -20.02
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Azenta Net Margin % Related Terms
Azenta Net Margin % Historical Data
* Premium members only.
The historical data trend for Azenta's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:BA3 vs KMTS, STAA, BLFS: Net Margin % Comparison
For the Medical Instruments & Supplies subindustry, Azenta's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Azenta Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Azenta's Net Margin % distribution charts can be found below:
* The bar in red indicates where Azenta's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Azenta (FRA:BA3) has a Net Margin % of 1.52% as of Jun. 2026. Net margin is the ratio of total net income to net sales. View historical data on Azenta and its competitors. This is 89% below median its historical median of 14.28. According to the industry distribution chart, Azenta ranks #568 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 69.7%.
Is Azenta's Net Margin % too high?
Azenta's current Net Margin % of 1.52% is 89% below median its 10-year median of 14.28. The Medical Devices & Instruments industry median Net Margin % is 2.20. Azenta's value of 1.52% is 30.9% below this industry median. Based on the distribution chart, Azenta ranks #568 out of 815 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Azenta has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Azenta's Net Margin % compare to KMTS and STAA?
According to the Medical Devices & Instruments industry distribution chart, Azenta ranks #568 out of 815 companies for Net Margin %. This places Azenta in the lower half of its industry. The industry median Net Margin % is 2.20. Azenta's value of 1.52% is 30.9% below this benchmark. While the company's 10-year median is 14.28 vs. the industry median of 2.20, Azenta has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.20, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Azenta's current Net Margin % of 1.52% is 30.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Azenta and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Azenta's current Net Margin % is 1.52%, which is 89% below median its own 10-year median of 14.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Azenta stock overvalued right now?
Based on GuruFocus' analysis, Azenta (FRA:BA3) is currently considered Significantly Undervalued. The stock's GF Value™ is €45.02, compared to a current price of €28.40 — trading 36.9% below its estimated fair value. The current Net Margin % is 1.52%, which is 89% below median its 10-year median of 14.28 and 30.9% below the Medical Devices & Instruments industry median of 2.20. Azenta's overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Azenta (FRA:BA3), the current Net Margin % is 1.52% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Azenta (FRA:BA3) Overvalued in 2026?
Based on GuruFocus' analysis, Azenta stock appears to be undervalued.
The current stock price of €28.40 is trading 36.9% below its estimated GF Value™ of €45.02.
GuruFocus considers Azenta to be Significantly Undervalued.
Key valuation signals for FRA:BA3:
Net Margin %: 1.52% (89% below median its 10-year median of 14.28)
GF Value™: €45.02 vs. price of €28.40 (36.9% below fair value)
Industry Position: 30.9% below the Medical Devices & Instruments median (#568 of 815)
No single metric tells the full story. See the FRA:BA3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.
78GF Score
Get the complete analysis for FRA:BA3
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BA3 has been successfully added to your 
